Fig. 2: Comparisons of published data for male patients with Fabry disease. | Genetics in Medicine

Fig. 2: Comparisons of published data for male patients with Fabry disease.

From: Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study

Fig. 2

Annualized changes in (a) renal function and (b) LVMi as reported in the literature for male patients who are either untreated or have been treated with migalastat or ERT. aChange from baseline calculated using the weighted average for end-stage renal disease subgroups (n = 128 males with non-end-stage renal disease and n = 17 males with end-stage renal disease). eGFR estimated glomerular filtration rate, ERT enzyme replacement therapy, LVMi left ventricular mass index.

Back to article page